Cargando…

Verteporfin-Loaded Lipid Nanoparticles Improve Ovarian Cancer Photodynamic Therapy In Vitro and In Vivo

Advanced ovarian cancer is the most lethal gynecological cancer, with a high rate of chemoresistance and relapse. Photodynamic therapy offers new prospects for ovarian cancer treatment, but current photosensitizers lack tumor specificity, resulting in low efficacy and significant side-effects. In th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Michy, Thierry, Massias, Thibault, Bernard, Claire, Vanwonterghem, Laetitia, Henry, Maxime, Guidetti, Mélanie, Royal, Guy, Coll, Jean-Luc, Texier, Isabelle, Josserand, Véronique, Hurbin, Amandine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896159/ https://www.ncbi.nlm.nih.gov/pubmed/31717427 http://dx.doi.org/10.3390/cancers11111760

Ejemplares similares

Tumor-Specific Imaging with Angiostamp800 or Bevacizumab-IRDye 800CW Improves Fluorescence-Guided Surgery over Indocyanine Green in Peritoneal Carcinomatosis
por: Josserand, Véronique, et al.
Publicado: (2022)

Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth
por: Bouclier, Celine, et al.
Publicado: (2020)

Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma
por: Jeannot, Victor, et al.
Publicado: (2016)

Photodynamic Therapy with Verteporfin for Corneal Neovascularization
por: Al-Torbak, Abdullah A.
Publicado: (2012)

Photodynamic Diagnosis and Therapy for Peritoneal Carcinomatosis: Emerging Perspectives
por: Xu, Si, et al.
Publicado: (2020)

Photodynamic Therapy With Verteporfin for Choroidal Neovascularization in Patients with Angioid Streaks
por: Lee, Jun Mok, et al.
Publicado: (2007)

Red Upconverter Nanocrystals Functionalized with Verteporfin for Photodynamic Therapy Triggered by Upconversion
por: Miletto, Ivana, et al.
Publicado: (2022)

Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties
por: Gilson, Pauline, et al.
Publicado: (2017)

Verteporfin photodynamic therapy of retinal capillary hemangioblastoma in von Hippel-Lindau disease
por: Bhattacharjee, Harsha, et al.
Publicado: (2010)

Retinal Capillary Hemangioma Treated with Verteporfin Photodynamic Therapy and Intravitreal Triamcinolone Acetonide
por: Suh, Shin Cho, et al.
Publicado: (2007)

Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Noh, Sung Rae, et al.
Publicado: (2019)

Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne(®)), in the CAM model
por: Debefve, E., et al.
Publicado: (2008)

Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks
por: Pece, Alfredo, et al.
Publicado: (2010)

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
por: Sanguansak, Thuss, et al.
Publicado: (2015)

Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer
por: Huggett, M T, et al.
Publicado: (2014)

Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy: A Review of Data and Efficacy
por: Iacono, Pierluigi, et al.
Publicado: (2020)

Photoproducts of the Photodynamic Therapy Agent Verteporfin Identified via Laser Interfaced Mass Spectrometry
por: Furlan, Chris, et al.
Publicado: (2020)

A case of presumed choroidal metastasis from carcinoid tumor treated by photodynamic therapy with verteporfin
por: Kawakami, Setsuko, et al.
Publicado: (2013)

Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK
por: Claxton, Lindsay, et al.
Publicado: (2014)

Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
por: Dhirani, Nadeem Ali, et al.
Publicado: (2017)

Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report
por: Ng, Winnie WK, et al.
Publicado: (2011)

Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration
por: Tsuchihashi, Takashi, et al.
Publicado: (2013)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
por: Fernández, Maribel, et al.
Publicado: (2012)

The Noninvasive Treatment for Sentinel Lymph Node Metastasis by Photodynamic Therapy Using Phospholipid Polymer as a Nanotransporter of Verteporfin
por: Shimada, Kyosuke, et al.
Publicado: (2017)

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
por: Lim, Tock H., et al.
Publicado: (2020)

In vitro effects of verteporfin on ocular cells
por: Ammar, David A., et al.
Publicado: (2013)

Anti-Cancer Activity of Verteporfin in Cholangiocarcinoma
por: Golino, Jihye L., et al.
Publicado: (2023)

Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
por: Jain, Prashant, et al.
Publicado: (2018)

Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment
por: Lu, Jingjing, et al.
Publicado: (2019)

Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
por: Fujita, Kyoko, et al.
Publicado: (2020)

Photodynamic Therapy Using Hippo Pathway Inhibitor Verteporfin: A Potential Dual Mechanistic Approach in Treatment of Soft Tissue Sarcomas
por: Rytlewski, Jeffrey D., et al.
Publicado: (2021)

Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Kumashiro, Shun, et al.
Publicado: (2021)

Docking analysis of verteporfin with YAP WW domain
por: Kandoussi, Ilham, et al.
Publicado: (2017)

Verteporfin as a Medical Treatment in Peyronie’s Disease
por: Mohede, Daan C.J., et al.
Publicado: (2018)

The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor
por: Wei, Changran, et al.
Publicado: (2020)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes
por: Gross, Nikolai, et al.
Publicado: (2013)

Commentary: Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy
por: Kumar, Atul, et al.
Publicado: (2018)

3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization
por: Hu, Yu-Chen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_69ut40kr2inaffqts6tht78fev